CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
  • Wed, 28-Apr-2021
  • Posted by: BIOCON
No Comments

Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
  • Mon, 29-Mar-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets

Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
  • Tue, 02-Mar-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
  • Mon, 01-Mar-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)

Biocon Biologics and Viatris Inc Receive CHMP Nod for Abevmy a Biosimilar to Avastin Bevacizumab
  • Mon, 01-Mar-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care
  • Tue, 16-Feb-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries
  • Thu, 04-Feb-2021
  • Posted by: BIOCON
No Comments

Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore

Biocon Q3FY21 Results
  • Fri, 22-Jan-2021
  • Posted by: BIOCON
No Comments

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
  • Thu, 21-Jan-2021
  • Posted by: BIOCON
No Comments

Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ

Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
  • Thu, 07-Jan-2021
  • Posted by: BIOCON
No Comments

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>